RenovoCath Used in First Sarcoma Patient, Expanding Beyond Pancreatic Cancer
RNXT sits 53% above its 52-week low of $0.701.
Summary
RenovoRx's FDA-cleared drug-delivery device, RenovoCath, has been used commercially for the first time in a sarcoma patient at CARTI Cancer Center, marking expansion beyond its core pancreatic cancer focus. Treatment began in late June 2026 and is ongoing, with early results encouraging. This milestone demonstrates the device's potential as a standalone product for other solid tumors, which could significantly broaden its market. The company reported record RenovoCath sales of $563,000 in Q1 2026, and this new application may accelerate adoption. The news follows recent positive developments including FDA Orphan Drug Designation for oxaliplatin and promising Phase III trial data. Upcoming KOL webinar on August 13 may provide further insights.
At the time of this announcement, RNXT was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.8M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.